Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2022 Earnings Call Transcript

John Poyhonen: Of course. So with respect to the sales ramp up, it will really be determined on how quickly we can get formulary approval. So that’s a key priority that we have right now. As with any of our products, we don’t give guidance to during a launch phase. So we’re really not providing any additional insights at this time. What we hope to do is continue to provide updates on the progress as we get further in, but we’re only two weeks out. With respect to the additional cost, we’re using our existing ZYNRELEF sales force. They call on the exact same audience. Our team is already calling on anesthesiologists, on pharmacy, on surgeons. And fortunately, there’s a tremendous overlap of the target accounts that we’re going after, especially the oral aprepitant accounts with the ZYNRELEF accounts that we have. So it’s a very small percentage of the overall budget that’s used incrementally to launch APONVIE compared to what we’re doing as a commercial spend.

Unidentified Analyst: Got it. Thank you.

Operator: And that does conclude the question-and-answer session. I would like to turn the call back over to Dr. Quart for any additional or closing remarks.

Barry Quart: Thank you, and thanks everyone for joining us today on the call. We look forward to keeping you updated in the future.

Operator: Ladies and gentlemen, that concludes today’s conference call. Thank you for your participation and you may now disconnect. Goodbye.